LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Strona główna・Stock List・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Closed

SectorHealthcare

29.44 -0.14

Buy Sell

Overview

Share price change

24h

Current

Min

28.82

Max

29.71

Key metrics
By Trading Economics
Income	-10M -67M
EPS	-1.01
Profit margin	-7,753.425
Employees	186
EBITDA	-3.2M -66M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+84.7% upside

Market Stats
By TradingEconomics
Market Cap	217M 1.7B
Previous open	29.58
Previous close	29.44

News Sentiment

By Acuity

50%

184 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

18.91 / 20.63 Support & Resistance

Celldex Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 gru 2025, 21:08 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms Buys AI-Device Maker Limitless

5 gru 2025, 19:39 UTC

Major Market Movers

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 gru 2025, 19:17 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

5 gru 2025, 21:59 UTC

Acquisitions, Mergers, Takeovers

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 gru 2025, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

5 gru 2025, 21:50 UTC

Acquisitions, Mergers, Takeovers

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 gru 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 gru 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 gru 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 gru 2025, 21:03 UTC

Market Talk

Earnings

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 gru 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 gru 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 gru 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 gru 2025, 20:42 UTC

Acquisitions, Mergers, Takeovers

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 gru 2025, 20:01 UTC

Acquisitions, Mergers, Takeovers

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 gru 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 gru 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 gru 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5 gru 2025, 19:31 UTC

Acquisitions, Mergers, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 gru 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 gru 2025, 18:28 UTC

Acquisitions, Mergers, Takeovers

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 gru 2025, 18:24 UTC

Acquisitions, Mergers, Takeovers

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5 gru 2025, 18:20 UTC

Market Talk

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5 gru 2025, 18:11 UTC

Market Talk

The Tale of Two Canadian Employment Indicators -- Market Talk

5 gru 2025, 17:48 UTC

Market Talk

Canadian Youth Unemployment Rate Cools -- Market Talk

5 gru 2025, 17:44 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

5 gru 2025, 17:44 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Correction to Imax Market Talk

5 gru 2025, 17:35 UTC

Market Talk

Canada Jobs Data Doesn't Jive With Trade Uncertainty, Indicators -- Market Talk

5 gru 2025, 17:25 UTC

Market Talk

Canadian Jobs Numbers May Support Rates Hikes Next Year -- Market Talk

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

84.7% upside

12 Months Forecast

Average 54.67 USD 84.7%

High 90 USD

Low 21 USD

Based on 10 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Celldex Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

18.91 / 20.63Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

184 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.